Basilea Pharmaceutica AG (BSLN.S)
31 Jul 2014
|Market Cap (Mil.):||CHF1,034.71|
|Shares Outstanding (Mil.):||10.48|
BRIEF-Basilea Pharmaceutica - enters into agreement with Quintiles for commercialization of Zevtera/Mabelio in Europe
July 21 - Basilea Pharmaceutica AG : * Says entered into agreement with Quintiles for commercialization of
Isavuconazole as Qualified Infectious Disease Product (QIDP) for oral and intravenous treatment of invasive candidiasis Source text for Eikon: Further company coverage:
July 17 - Basilea Pharmaceutica AG : * Submits Isavuconazole European marketing authorization application for the
ZURICH, June 25 - Shares in Swiss biotech company Basilea fell by as much as 11.5 percent in early trading on Wednesday following a setback to its efforts to gain U.S. approval for its ceftobiprole treatment for pneumonia.
ZURICH, June 25 - Shares in Swiss biotech company Basilea fell 8 percent in early trading on Wednesday following a setback to its efforts to gain U.S. approval for its ceftobiprole treatment for pneumonia.
June 25 - Basilea Pharmaceutica AG : * Says FDA confirmed that a potential regulatory approval of ceftobiprole in
ZURICH, June 12 - Swiss biotech company Basilea said it had started an early-stage clinical study of an antibiotic to treat infections with multi-drug resistant Gram-negative bacteria in combination with another drug.
Earnings vs. Estimates
Analyst Research Reports
Basilea Pharmaceutica AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Wright Reports
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.